Kodiak Sciences Inc.
KOD
Clasificación en acciones
#3071
Kodiak Sciences Inc. is a biopharmaceutical firm currently in the clinical... Kodiak Sciences Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to discovering, advancing, and bringing to market treatments for various conditions affecting the retina. Their primary drug candidate, KSI-301, is an anti-vascular endothelial growth factor (anti-VEGF) antibody biopolymer. This compound is currently undergoing Phase IIb/III clinical trials, targeting illnesses such as wet age-related macular degeneration (AMD), diabetic macular edema, previously untreated macular edema resulting from retinal vein occlusion, and non-proliferative diabetic retinopathy. In its earlier, preclinical development pipeline, the company is also working on KSI-501, a bispecific conjugate designed for retinal conditions involving inflammation, and KSI-601, a triplet inhibitor aimed at addressing dry AMD. Established in 2009, this Palo Alto, California-based company operated under the name Oligasis, LLC before rebranding as Kodiak Sciences Inc. in September 2015.
Precio por acción
$93.69
Capitalización bursátil
$5.89B
Cambio (1 día)
2.56%
Cambio (1 año)
429.32%
País
US
Comercio Kodiak Sciences Inc. (KOD)
Categoría
Healthcare
Historial de desdoblamientos de acciones de Kodiak Sciences Inc. (KOD)
La acción Kodiak Sciences Inc. (símbolo: KOD) tuvo un total de 1 desdoblamientos.
El desdoblamiento más reciente ocurrió el Feb 23, 2022.
Una acción KOD comprada antes de Feb 23, 2022 equivaldría hoy a 5 acciones KOD.
El desdoblamiento más reciente ocurrió el Feb 23, 2022.
Una acción KOD comprada antes de Feb 23, 2022 equivaldría hoy a 5 acciones KOD.
Lista de desdoblamientos de acciones
| Año | Desdoblamiento | Multiplicador | Multiplicador acumulado |
|---|---|---|---|
| 2022-02-23 | 5:1 | x5 | x5 |
Desdoblamientos de acciones de empresas similares o competidoras
| Empresa | Número de desdoblamientos de acciones | Multiplicador acumulado | País |
|---|---|---|---|
| 1 | x2 |
US
|
|
| 0 | - |
US
|
|
| 1 | x3 |
AU
|
|
| 0 | - |
CH
|
|
| 0 | - |
NL
|
